Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Feasibility and preliminary efficacy of a Mediterranean diet and home-based exercise intervention during chemotherapy for lymphoma survivors: The life-l study

Melissa Lopez-Pentecost, Tracy Crane, Akina Natori, Juan Alderuccio, Alvaro Alencar, Michele Stanchina, Georgios Pongas, Asaad Trabolsi, Jonathan Schatz, Ashley Rose, David Lessen, Joseph Rosenblatt, Izidore S. Lossos, Juan Carlos Ramos, Russ Kuker, Craig Moskowitz

Blood (2025) 146 (Supplement 1): 4547.

https://doi.org/10.1182/blood-2025-4547

Published: 2025

Journal Articles

Adherence to the 2018 world cancer research fund/American institute for cancer research cancer prevention recommendations and mortality among blood cancer survivors

LaShae Rolle, Harleen Kaur, Melissa Lopez-Pentecost, Coral Levkovitz, Abhishek Pandey, Ola Landgren, Craig Moskowitz, Tracy Crane

Blood (2025) 146 (Supplement 1): 4538.

https://doi.org/10.1182/blood-2025-4538

Published: 2025

Journal Articles

Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2025-1009

Published: 2025

Journal Articles

Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial

Blood (2025) 146 (Supplement 1): 1850.

https://doi.org/10.1182/blood-2025-1850

Published: 2025

Journal Articles

First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctdna analysis from dose escalation

Swetha Thiruvengadam, Christina Poh, Ryan Lynch, Craig Moskowitz, Michael Spinner, Martin Hutchings, Cristina García Herce, Elizabeth Phillips, Aung Tun, Julie Vose, Mina Nayeri, Erika Rudnicki, Maria Delioukina, Michelle Fanale, Sujit Biswas, Hailing Lu, Carlo Visco

Blood (2025) 146 (Supplement 1): 155.

https://doi.org/10.1182/blood-2025-155

Published: 2025

Journal Articles

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 151.

https://doi.org/10.1182/blood-2025-151

Published: 2025

Journal Articles

Risk Factors and a Prognostic Score for Progression Free Survival after Treatment with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin Lymphoma (rrHL)

Paul J Bröckelmann, MD, Horst Müller, PhD, Olivier Casasnovas, MD, Martin Hutchings, MD, Bastian von Tresckow, MD, Peter Borchmann, MD, Craig Moskowitz, MD, Andreas Engert, MD

Blood (2015) 126 (23): 1978.

https://doi.org/10.1182/blood.V126.23.1978.1978

Published: 2015

Journal Articles

Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study

Eric Van Den Neste, MD PhD, Norbert Schmitz, MD, Nicolas Mounier, MD PhD, Devinder Gill, MB FRCPath FRACP FRCPA, Marek Trneny, MD, PhD, Prof., Noel Milpied, John A. Radford, MD, Nicolas Ketterer, Ofer Shpilberg, MD, Ulrich Dührsen, David Ma, MD, Josette Briere, Catherine Thieblemont, Gilles A. Salles, MD PhD, Craig Moskowitz, MD, Bertran Glass, Christian Gisselbrecht

Blood (2015) 126 (23): 517.

https://doi.org/10.1182/blood.V126.23.517.517

Published: 2015

Journal Articles

Sequential Dose-Dense RCHOP Followed by ICE Consolidation (MSKCC protocol 01–142) without Radiotherapy for Patients with Primary Mediastinal Large B Cell Lymphoma

Craig Moskowitz, MD, Paul A Hamlin, Jr., Jocelyn Maragulia, Jessica Meikle, Andrew D Zelenetz, MD

Blood (2010) 116 (21): 420.

https://doi.org/10.1182/blood.V116.21.420.420

Published: 2010

Journal Articles

Impact of Routine Surveillance Imaging on the Outcome of Patients with Relapsed Hodgkin Lymphoma.

Basciano A. Basciano, MD, Craig Moskowitz, MD, Andrew D. Zelenetz, MD, PhD

Blood (2009) 114 (22): 1558.

https://doi.org/10.1182/blood.V114.22.1558.1558

Published: 2009

Journal Articles

Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant- Eligible Relapsed and Primary Refractory Hodgkin Lymphoma

Alison J. Moskowitz, MD, Stephen D. Nimer, Andrew D. Zelenetz, MD, PhD, Tarun Kewalramani, MD, Jill M Vanak, ACNP, Jocelyn c Maragulia, Joachim Yahalom, MD, Craig Moskowitz, MD

Blood (2008) 112 (11): 776.

https://doi.org/10.1182/blood.V112.11.776.776

Published: 2008

Journal Articles

Sequential Chemotherapy Followed by High Dose Therapy and Autologous Stem Cell Rescue for Mantle Cell Lymphoma: Impact of MIB-1 on Outcome

Andrew D Zelenetz, MD, PhD, Craig Moskowitz, MD, Jocelyn Maragulia, Carol S. Portlock, Julie Teruya-Feldstein

Blood (2008) 112 (11): 3759.

https://doi.org/10.1182/blood.V112.11.3759.3759

Published: 2008

Journal Articles

Vaccine Efficacy Following Autologous Peripheral Blood Stem Cell Transplant for Lymphoma.

Trudy N. Small, MD, Robert D. Rice, RN, Emily McCullagh, Ariela Noy, Tanya Trippett, Steven M. Horwitz, Andrew D. Zelenetz, Craig Moskowitz

Blood (2007) 110 (11): 603.

https://doi.org/10.1182/blood.V110.11.603.603

Published: 2007

Journal Articles

R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study.

Christian Gisselbrecht, MD, Norbert Schmitz, MD, Nicolas Mounier, MD, PhD, David Ma, MD, Marek Trneny, MD, Hans Hagberg, MD, David C. Linch, MD, Ofer Shpilberg, MD, Nicolas Ketterer, MD, Bertram Glass, MD, Andre Bosly, MD, Devinder Gill, MD, Philippe Gaulard, MD, Craig Moskowitz, MD

Blood (2007) 110 (11): 517.

https://doi.org/10.1182/blood.V110.11.517.517

Published: 2007

Journal Articles

Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL.

Craig Moskowitz, MD, Paul A. Hamlin, MD, Steven M. Horwitz, MD, Ariela Noy, MD, Owen A. O’Connor, MD,PhD, M. Lia Palomba, MD, Carol S. Portlock, MD, David J. Straus, MD, Simone Chennin-Lessac, Alandra Weaver, Julie Teruva-Feldstein, MD, Heiko Schoder, MD, Andrew D. Zelenetz, MD,PhD

Blood (2006) 108 (11): 532.

https://doi.org/10.1182/blood.V108.11.532.532

Published: 2006

Journal Articles

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

John Gerecitano, MD, PhD, Carol Portlock, MD, Ariela Noy, MD, Paul Hamlin, MD, Craig Moskowitz, MD, David Straus, MD, Steven M. Horwitz, MD, Maria Lia Palomba, MD, Otilia-Liana Dumitrescu, MD, Jennifer Pappanicholaou, Ellen Neylon, Rachel Hamelers, Andrew Zelenetz, MD,PhD, Thomas J. Myers, MD, Anthony L. Boral, MD, Owen A. O’Connor, MD,PhD

Blood (2006) 108 (11): 2759.

https://doi.org/10.1182/blood.V108.11.2759.2759

Published: 2006

Journal Articles

Is it time to stop treating subsets of DLBCL with R-CHOP?

Craig Moskowitz

Blood (2006) 107 (11): 4197–4198.

https://doi.org/10.1182/blood-2006-03-008995

Published: 2006

Journal Articles

Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.

Steven Horwitz, MD, Craig Moskowitz, MD, Tarun Kewalramani, MD, Paul Hamlin, MD, David Straus, MD, Owen O’Connor, MD, PhD, Ariela Noy, MD, Carol Portlock, MD, Stephen Nimer, MD, PhD, M. Lia Palomba, MD, PhD, Andrew Zelenetz, MD, PhD

Blood (2005) 106 (11): 2679.

https://doi.org/10.1182/blood.V106.11.2679.2679

Published: 2005

Journal Articles

Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease

David J. Straus, Carol S. Portlock, Jing Qin, Jane Myers, Andrew D. Zelenetz, Craig Moskowitz, Ariela Noy, André Goy, Joachim Yahalom

Blood (2004) 104 (12): 3483–3489.

https://doi.org/10.1182/blood-2004-04-1311

Published: 2004

Journal Articles

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

Owen O’Connor, MD, PhD, John Wright, Craig Moskowitz, MD, Barbara MacGregor-Cortelli, RN, David Straus, MD, Andrew Evans, MD, Jane Winter, MD, Omer Koc, MD, Nancy Horvath, RN, Susan Blumel, MD, Julie Vose, MD, David Schenkein, MD, Andrew Zelenetz, MD

Blood (2004) 104 (11): 607.

https://doi.org/10.1182/blood.V104.11.607.607

Published: 2004

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Feasibility and preliminary efficacy of a Mediterranean diet and home-based exercise intervention during chemotherapy for lymphoma survivors: The life-l study

Adherence to the 2018 world cancer research fund/American institute for cancer research cancer prevention recommendations and mortality among blood cancer survivors

Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell lymphoma

Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial

First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctdna analysis from dose escalation

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

Risk Factors and a Prognostic Score for Progression Free Survival after Treatment with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin Lymphoma (rrHL)

Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study

Sequential Dose-Dense RCHOP Followed by ICE Consolidation (MSKCC protocol 01–142) without Radiotherapy for Patients with Primary Mediastinal Large B Cell Lymphoma

Impact of Routine Surveillance Imaging on the Outcome of Patients with Relapsed Hodgkin Lymphoma.

Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant- Eligible Relapsed and Primary Refractory Hodgkin Lymphoma

Sequential Chemotherapy Followed by High Dose Therapy and Autologous Stem Cell Rescue for Mantle Cell Lymphoma: Impact of MIB-1 on Outcome

Vaccine Efficacy Following Autologous Peripheral Blood Stem Cell Transplant for Lymphoma.

R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study.

Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL.

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

Is it time to stop treating subsets of DLBCL with R-CHOP?

Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.

Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only